These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
742 related articles for article (PubMed ID: 27816292)
1. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Craiglow BG; Liu LY; King BA J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292 [TBL] [Abstract][Full Text] [Related]
2. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Liu LY; Craiglow BG; Dai F; King BA J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293 [TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Almutairi N; Nour TM; Hussain NH Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941 [TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial. Paracha M; Wasim M; Noor SM; Khan AQ; Sagheer F; Ahmad I Arch Dermatol Res; 2024 Jul; 316(7):458. PubMed ID: 38967866 [TBL] [Abstract][Full Text] [Related]
5. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. Liu LY; Craiglow BG; King BA J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908 [No Abstract] [Full Text] [Related]
6. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study. Jerjen R; Meah N; Trindade de Carvalho L; Wall D; Eisman S; Sinclair R Pediatr Dermatol; 2021 Jan; 38(1):103-108. PubMed ID: 33099833 [TBL] [Abstract][Full Text] [Related]
7. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Akdogan N; Ersoy-Evans S; Doğan S; Atakan N Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150 [TBL] [Abstract][Full Text] [Related]
8. Tofacitinib as a treatment of alopecia areata in adolescents. Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654 [TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib. Cheng MW; Kehl A; Worswick S; Goh C J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tofacitinib in 97 alopecia areata patients. Nasimi M; Abedini R; Ghandi N; Teymourpour A; Babaie H J Cosmet Dermatol; 2024 Sep; 23(9):2807-2813. PubMed ID: 38736269 [TBL] [Abstract][Full Text] [Related]
11. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252 [TBL] [Abstract][Full Text] [Related]
13. Tofacitinib therapy for children with severe alopecia areata. Dai YX; Chen CC J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026 [No Abstract] [Full Text] [Related]
14. Excellent response to tofacitinib treatment in a patient with alopecia universalis. Erduran F; Adışen E; Aksakal AB Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888 [TBL] [Abstract][Full Text] [Related]
15. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. Guo L; Feng S; Sun B; Jiang X; Liu Y J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993 [TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman. Mrowietz U; Gerdes S; Gläser R; Schröder O Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217 [No Abstract] [Full Text] [Related]
17. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121 [TBL] [Abstract][Full Text] [Related]
18. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents. Liu LY; King BA J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099 [TBL] [Abstract][Full Text] [Related]
19. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review. Benton S; Farah R; Freese R; Hordinsky M Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Jian J; Li M; Qian P; Li J; Tang Y; Liu F; Zhao Z; Huang J; Shi W Arch Dermatol Res; 2024 May; 316(5):154. PubMed ID: 38734794 [No Abstract] [Full Text] [Related] [Next] [New Search]